HIDRADENITIS SUPPURATIVA

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 participants who were in earlier studies will receive the drug as an injection under the s…

This study tests a drug called sonelokimab in 35 teens aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. The goal is to see how the drug moves through the body and if it is safe. Participants receive injections over 24 weeks, and docto…

This study tests whether brensocatib can reduce painful bumps and abscesses in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. About 214 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if brensoc…

This study tests an investigational drug called lutikizumab for adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease causing painful lumps and scars. The main part of the study includes about 160 people who have not responded to anti-TNF therapy, w…

This study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a painful skin condition. Participants receive either the drug or a placebo to see if it reduces abscesses and inflammation by at least half after 16 weeks. The goal is…

This early-stage study tests a new drug called SBT777101 in 24 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to check safety and how the body handles a single dose, with doses increasing only after lo…

This study tests whether anifrolumab, a drug that blocks certain immune processes, can help people with hidradenitis suppurativa (HS) — a painful skin condition causing boils and tunnels. About 15 adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks…

This study looks at the long-term safety of the drug bimekizumab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 658 adults who completed earlier studies will continue receiving bimekizumab for up to 48 weeks. The main goal is to …

This study follows about 434 adults with moderate to severe hidradenitis suppurativa (a painful skin condition) who are taking the drug secukinumab. Researchers want to see how doctors adjust the dose over two years and how well the treatment controls symptoms like abscesses and …

This study tests five different experimental drugs in people with moderate to severe hidradenitis suppurativa, a painful skin condition that causes abscesses and tunnels under the skin. The goal is to see if these drugs can reduce the number of abscesses and inflamed bumps withou…

This study tests an experimental drug called eltrekibart in 352 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and abscesses. The goal is to find the safest and most effective dose to reduce flare-ups and skin pain. Partic…

This study looks at how well the drug secukinumab works over the long term for people with moderate to severe hidradenitis suppurativa, a painful skin condition. About 700 adults who completed a previous year-long study will either continue or pause treatment to see if symptoms s…

This study aims to understand how well the drug secukinumab works for adults with moderate to severe hidradenitis suppurativa (HS) in real-world Russian clinics. Researchers will observe 107 patients already prescribed this medication by their doctors as part of normal care. The …

This study planned to test a fractional ablative erbium laser on scarring caused by hidradenitis suppurativa (HS) in the armpit area. It aimed to see if the laser could safely reduce scar severity and improve patient satisfaction. However, the study was withdrawn before any parti…

This study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are with the medication secukinumab, and how it affects their quality of life. About 48 adults in the UAE who are starting secukinumab will fill out questionnaires over a short period. …

This study follows 192 adults with hidradenitis suppurativa (HS) for 12 months after they start taking secukinumab. Researchers ask patients to rate their pain, oozing, and bad smell on a 0-10 scale. The goal is to see how many patients get at least a 30% reduction in these sympt…

This study looks at how hidradenitis suppurativa (HS) affects physical activity and tests a custom exercise program designed to improve strength and daily function. Researchers will measure changes in leg and hand strength, walking ability, and quality of life in 86 adults with H…

This study planned to see if gentian violet, a purple dye, could ease symptoms of hidradenitis suppurativa (a painful skin condition). Participants would have rated changes in redness, drainage, and pain. However, the study was withdrawn before any volunteers enrolled, so no resu…

This study aimed to see if Botulinum Toxin-A (Botox) could help people with hidradenitis suppurativa, a painful skin condition. It planned to enroll adults with active armpit lesions and measure changes in lesion count and quality of life. However, the study was withdrawn before …

This study tested a 1726nm laser (AviClear) on 8 adults with mild to moderate hidradenitis suppurativa (HS), a painful skin condition. The goal was to see if the laser safely reduces painful bumps and lesions. Researchers measured improvement using a standard score (HiSCR50) and …

This study is creating a large registry of 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants in regular clinics to see how well current and new treatments work and what side effects occur. The g…